ACCELERON PHARMA INC Insider Trading for April 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ACCELERON PHARMA INC for April 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Option Exercise | M | 40.61 | 7,500 | 304,575 | 0 | |
| Apr 21 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Sell | S | 121.23 | 200 | 24,246 | 6,044 | 6.2 K to 6 K (-3.20 %) |
| Apr 21 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Sell | S | 120.16 | 1,143 | 137,343 | 6,244 | 7.4 K to 6.2 K (-15.47 %) |
| Apr 21 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Sell | S | 119.36 | 4,030 | 481,021 | 7,387 | 11.4 K to 7.4 K (-35.30 %) |
| Apr 21 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Sell | S | 118.39 | 2,127 | 251,816 | 11,417 | 13.5 K to 11.4 K (-15.70 %) |
| Apr 21 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Buy | M | 40.61 | 7,500 | 304,575 | 13,544 | 6 K to 13.5 K (+124.09 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | M | 24.11 | 10,000 | 241,100 | 0 | |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Sell | S | 142.27 | 1,100 | 156,497 | 34,499 | 35.6 K to 34.5 K (-3.09 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Sell | S | 141.28 | 2,152 | 304,035 | 35,599 | 37.8 K to 35.6 K (-5.70 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Sell | S | 140.31 | 6,748 | 946,812 | 37,751 | 44.5 K to 37.8 K (-15.16 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Buy | M | 24.11 | 10,000 | 241,100 | 44,499 | 34.5 K to 44.5 K (+28.99 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 52.99 | 2,050 | 108,630 | 4,085 | |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 41.64 | 1,875 | 78,075 | 3,750 | |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 35.34 | 5,000 | 176,700 | 10,000 | |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 141.15 | 641 | 90,477 | 1,622 | 2.3 K to 1.6 K (-28.33 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 140.13 | 11,223 | 1,572,679 | 2,263 | 13.5 K to 2.3 K (-83.22 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 52.99 | 2,050 | 108,630 | 13,486 | 11.4 K to 13.5 K (+17.93 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 41.64 | 1,875 | 78,075 | 11,436 | 9.6 K to 11.4 K (+19.61 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 35.34 | 5,000 | 176,700 | 9,561 | 4.6 K to 9.6 K (+109.63 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | M | 24.11 | 10,000 | 241,100 | 10,000 | |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Sell | S | 135.67 | 1,600 | 217,072 | 34,499 | 36.1 K to 34.5 K (-4.43 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Sell | S | 135.22 | 1,700 | 229,874 | 36,099 | 37.8 K to 36.1 K (-4.50 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Sell | S | 134.27 | 6,596 | 885,645 | 37,799 | 44.4 K to 37.8 K (-14.86 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Sell | S | 132.61 | 104 | 13,791 | 44,395 | 44.5 K to 44.4 K (-0.23 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Buy | M | 24.11 | 10,000 | 241,100 | 44,499 | 34.5 K to 44.5 K (+28.99 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 52.99 | 2,050 | 108,630 | 6,135 | |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 41.64 | 1,875 | 78,075 | 5,625 | |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 35.34 | 5,000 | 176,700 | 15,000 | |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 137.92 | 941 | 129,783 | 4,561 | 5.5 K to 4.6 K (-17.10 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 136.92 | 3,796 | 519,748 | 5,502 | 9.3 K to 5.5 K (-40.83 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 136.22 | 2,987 | 406,889 | 9,298 | 12.3 K to 9.3 K (-24.31 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 134.54 | 1,201 | 161,583 | 12,285 | 13.5 K to 12.3 K (-8.91 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 52.99 | 2,050 | 108,630 | 13,486 | 11.4 K to 13.5 K (+17.93 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 41.64 | 1,875 | 78,075 | 11,436 | 9.6 K to 11.4 K (+19.61 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 35.34 | 5,000 | 176,700 | 9,561 | 4.6 K to 9.6 K (+109.63 %) |